SAN FRANCISCO, April 06, 2021 (GLOBE NEWSWIRE) -- XpresSpa Group, Inc. (Nasdaq: XSPA) (“XpresSpa” or the “Company”), a health and wellness company, today announced that it has signed a contract to open a new COVID-19 testing facility in the San Francisco International Airport. This location is expected to open in mid-April.

XpresCheck will be building a pop-up facility, pre-security, near the baggage claim area on the Arrivals level at Terminal 3. It will host nine separate testing rooms with an anticipated capacity to administer over 500 tests per day. COVID-19 testing options will include the Rapid Molecular COVID-19 Test and the Polymerase Chain Reaction (PCR) Test.

Doug Satzman, XpresSpa CEO, stated, "We are thrilled to be leveraging our existing relationship with United Airlines to bring a new XpresCheck testing facility to the San Francisco International Airport. We are pleased to continue to support United’s efforts to provide their customers with testing options to meet their destination entry requirements with our easy rapid molecular testing protocol and convenient on-site testing facilities. We believe providing this additional layer of safety will be helpful to passengers and airline employees as demand for travel continues to accelerate throughout 2021.”

“United has always said that until there is a widely distributed vaccine, testing is the key to opening domestic and international travel,” said Lori Augustine, vice president of United’s San Francisco hub. “With the addition of this new XpresCheck location, United customers traveling through San Francisco have access to yet another convenient testing option to help them meet the entry requirements at their final destination or provide them with peace of mind ahead of their flight.”

“We welcome the addition of an XpresCheck™ COVID-19 Pop-Up Testing Facility at SFO,” said Airport Director Ivar C. Satero. “As the first airport in the U.S. to launch an onsite rapid testing capability, we understand the importance of giving travelers convenient on-airport testing options. We thank both United Airlines and the XpresSpa Group for bringing this concept to SFO.”

About XpresSpa Group, Inc. 

XpresSpa Group, Inc. (Nasdaq: XSPA) is a leading global health and wellness holding company. XpresSpa Group’s core asset, XpresSpa, is a leading airport retailer of spa services and related health and wellness products, with 45 locations in 23 airports globally. Through its XpresTest, Inc. subsidiary, the Company provides COVID-19 screening and testing under the XpresCheck™ brand at eleven locations in nine airports: Boston Logan International Airport (2), Denver International Airport, Dulles International Airport, Houston George Bush Intercontinental Airport, JFK International Airport, Newark Liberty International Airport (2), Phoenix Sky Harbor International Airport, Reagan National Airport, and Salt Lake City International Airport. To learn more about XpresSpa Group, visit: www.XpresSpaGroup.com.

Twitter: @xprescheck and Instagram: @realxprescheck

About United Airlines

United's shared purpose is "Connecting People. Uniting the World." For more information, visit united.com, follow @United on Twitter and Instagram or connect on Facebook. The common stock of United's parent, United Airlines Holdings, Inc., is traded on the Nasdaq under the symbol "UAL".

About San Francisco International Airport

SFO wants you to Travel Well. SFO works with local, state, and federal health officials to protect against COVID-19. Measures include enhanced cleaning protocols, hundreds of hand sanitizer stations, physical barriers, face coverings for everyone, and physical distancing. To learn more visit flysfo.com/travel-well.

SFO offers nonstop service to Asia, South Pacific, Europe, Canada, Mexico, and across the United States. For up-to-the-minute departure and arrival information, airport maps and details on shopping, dining, cultural exhibitions, ground transportation and more, visit www.flysfo.com. Follow us on www.twitter.com/flysfo and www.facebook.com/flysfo.

Forward-Looking Statements

This press release may contain "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. These include statements preceded by, followed by or that otherwise include the words "believes," "expects," "anticipates," "estimates," "projects," "intends," "should," "seeks," "future," "continue," or the negative of such terms, or other comparable terminology. In particular, these statements include, without limitation, statements about our expectations relating to our new XpresCheck™ concept, being able to expand testing to other communicable diseases as well as administer vaccinations for the seasonal flu, our positioning to be part of the national rollout of various COVID-19 vaccinations, the degree to which our public testing model assists passengers meet testing requirements in select states and countries, our ability to identify and gain access to the latest and best COVID-19 testing methodologies and equipment, and our overall ability to manage the regulatory challenges associated with this business line. Forward-looking statements relating to expectations about future results or events are based upon information available to XpresSpa Group as of today's date and are not guarantees of the future performance of the company, and actual results may vary materially from the results and expectations discussed. Additional information concerning these and other risks is contained in XpresSpa Group’s most recently filed Annual Report on Form 10-K, Quarterly Report on Form 10-Q, recent Current Reports on Form 8-K and other Securities and Exchange Commission filings. All subsequent written and oral forward-looking statements concerning XpresSpa Group, or other matters and attributable to XpresSpa Group or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements above. XpresSpa Group does not undertake any obligation to publicly update any of these forward-looking statements to reflect events or circumstances that may arise after the date hereof.

Investor Relations:
ICR
Raphael Gross
ir@xpresspagroup.com
(203) 682-8253

Media:
Julie Ferguson
Julie@jfprmedia.com
(312) 385-0098

Source: XpresSpa Group, Inc.